Skip to main content
. Author manuscript; available in PMC: 2020 Jul 28.
Published in final edited form as: Nat Med. 2019 Oct 7;25(10):1607–1614. doi: 10.1038/s41591-019-0584-2

Extended Data Fig. 8 |. Resistance to a targeted anti-epidermal growth factor receptor therapy, cetuximab, in KRAS mutant compared with KRAS wild type tumoroids.

Extended Data Fig. 8 |

Resistance to cetuximab is demonstrated in KRAS mutant RC tumoroids (blue) compared with a KRAS wild type tumoroids (orange). Dose range was used as shown and percentage of live cells is displayed for each tumoroid. Results are from two independent experiments done in technical quadruplicate; mean ± s.e.m.